Related references
Note: Only part of the references are listed.Routine Use of Oncotype DX Recurrence Score Testing in Node-Positive Hormone Receptor-Positive HER2-Negative Breast Cancer: The Time Has Come
Elizabeth A. Mittendorf et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
A. Matikas et al.
ANNALS OF ONCOLOGY (2019)
Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data
Amila Orucevic et al.
BREAST (2019)
Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline
N. Lynn Henry et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Gene-expression Profiling - A Decision Impact Analysis: Decision Dependency on Oncotype DX® as a Function of Oncological Work Experience in 117 Cases
Christian Eichler et al.
ANTICANCER RESEARCH (2019)
Breast Cancer in Young Women: Status Quo and Advanced Disease Management by a Predictive, Preventive, and Personalized Approach
Erik Kudela et al.
CANCERS (2019)
Oncotype DX for Comprehensive Treatment in Male Breast Cancer: A Case Report and Literature Review
Ang Zheng et al.
AMERICAN JOURNAL OF MENS HEALTH (2019)
Use of adjuvant chemotherapy in hormone receptor-positive breast cancer patients with or without the 21-gene expression assay
Soo Jin Park et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Uptake of BRCA 1/2 and oncotype DX testing by medical and surgical oncologists
Yonina R. Murciano-Goroff et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada
Sofia Torres et al.
ONCOLOGIST (2018)
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial
Ulrike Nitz et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer
Terri P. McVeigh et al.
BREAST CANCER-TARGETS AND THERAPY (2017)
Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK
J. Loncaster et al.
EJSO (2017)
Influence of a 21-Gene Recurrence Score Assay on Chemotherapy Delivery in Breast Cancer
Charles E. Rutter et al.
CLINICAL BREAST CANCER (2016)
The Value of Personalizing Medicine: Medical Oncologists' Views on Gene Expression Profiling in Breast Cancer Treatment
Yvonne Dombard et al.
ONCOLOGIST (2015)
Chemotherapy benefit for 'ER-positive' breast cancer and contamination of Nonluminal subtypes-waiting for TAILORx and RxPONDER
Z. Sun et al.
ANNALS OF ONCOLOGY (2015)
Tumor Biology Correlates With Rates of Breast-Conserving Surgery and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer Findings From the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial
Judy C. Boughey et al.
ANNALS OF SURGERY (2014)
Experiences and attitudes toward risk of recurrence testing in women with breast cancer: a systematic review
Laura E. Leggett et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Impact of Oncotype DX Recurrence Score in the Management of Breast Cancer Cases
Michaela T. Nguyen et al.
CLINICAL BREAST CANCER (2014)
Factors influencing Oncotype DX use in the management of early breast cancer: A single centre experience
Xiaofu Zhu et al.
EUROPEAN JOURNAL OF CANCER (2014)
The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use
W. Eiermann et al.
ANNALS OF ONCOLOGY (2013)
The impact of a genomic assay (Oncotype DX) on adjuvant treatment recommendations in early breast cancer
Richard H. de Boer et al.
MEDICAL JOURNAL OF AUSTRALIA (2013)
Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER plus ) node-negative breast cancer
J. Albanell et al.
ANNALS OF ONCOLOGY (2012)
Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen
A. Prat et al.
ANNALS OF ONCOLOGY (2012)
Improving communication of breast cancer recurrence risk
Noel T. Brewer et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Size surprise? Tumour size, nodal status, and outcome after breast cancer
W. D. Foulkes
CURRENT ONCOLOGY (2012)
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
K. Albain et al.
LANCET (2012)
Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20
Gong Tang et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor-Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20
Eleftherios P. Mamounas et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prospective Multicenter Study of the Impact of the 21-Gene Recurrence Score Assay on Medical Oncologist and Patient Adjuvant Breast Cancer Treatment Selection
Shelly S. Lo et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study
Mitch Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
Kathy S. Albain et al.
LANCET ONCOLOGY (2010)
Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies
Fiona M. Blows et al.
PLOS MEDICINE (2010)
The Influence of a Gene Expression Profile on Breast Cancer Decisions
Leonard R. Henry et al.
JOURNAL OF SURGICAL ONCOLOGY (2009)
Recent advances in systemic therapy New diagnostics and biological predictors of outcome in early breast cancer
Catherine Oakman et al.
BREAST CANCER RESEARCH (2009)
Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
Juhi Asad et al.
AMERICAN JOURNAL OF SURGERY (2008)
Development of the 21-gene assay and its application in clinical practice and clinical trials
Joseph A. Sparano et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Analytical validation of the oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer
Maureen Cronin et al.
CLINICAL CHEMISTRY (2007)
Treatment of lymph-node-negative, oestrogen-recept-postive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials
B Fisher et al.
LANCET (2004)
Share Paper
